Davis, R.J.

pegvisomant serum patient concentration octreotide tumor size treatment igf-i tumor acromegaly level serum igf-i concentrations increase library erasmus mc study serum gh concentrations therapy endocrinol growth antagonist disease activity field defects metab field acromegalic control disease defect october november serum gh concentration cotreatment gh levels gh /igf axis acromegalic patients period clin endocrinol serum pegvisomant concentrations result 3015 gd rotterdam somatostatin analogs serum gh levels igf-i levels hormone injection t.i.d 2000. erasmu receptor decrease activity month normalization katznelson l gh concentrations octreotide treatment efficacy data igf-i concentrations outcome efficacy action pegvisomant concentrations downloaded chiasm somatostatin gh molecule analog ghr antagonist library pegvisomant therapy b 2036- march acromegalic patient improvement 34- yr-old serum igf-i levels observation references 1. bates van der lely serum igf-i concentration